PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
September 13, 2022European Journal of Clinical InvestigationOpen Access

Comparison of pan‐immune‐inflammation value with other inflammation markers of long‐term survival afterST‐segment elevation myocardial infarction

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does the pan-immune-inflammation value (PIV) predict long-term mortality better than other inflammation markers in patients with ST-segment elevation myocardial infarction?

Population

Patients with ST-segment elevation myocardial infarction (STEMI)

Comparison

Pan-immune-inflammation value (PIV) vs Other inflammation markers

Design

Cohort

Follow-up

long-term

Authors

MÇMurat ÇaylıSMSelda MuratMÖMehmet Özgeyik

Discussion

Loading...

Member takes

Overview

May aid post-STEMI risk stratification; leaves open prospective validation before any practice change.

Structured PICO

Does the pan-immune-inflammation value (PIV) predict long-term mortality better than other inflammation markers in patients with ST-segment elevation myocardial infarction?

P
Population
Patients with ST-segment elevation myocardial infarction (STEMI)
I
Intervention
Pan-immune-inflammation value (PIV)
C
Comparator
Other inflammation markers
O
Outcome
Long-term survival (mortality)hard clinical

The pan-immune-inflammation value (PIV) may serve as a superior prognostic biomarker for long-term mortality in patients following STEMI.

Limitations

  • Requires prospective validation

Cite This Study

Çaylı et al. (2022) studied this question.

synapsesocial.com/papers/69d9d9ca0d540cafc5837b40https://doi.org/10.1111/eci.13872
View Full Paper
Ask AI
Bookmark
Share